(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

K KNACK PHARMACEUTICALS

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

K KNACK PHARMACEUTICALS

ST13

US500000087818037

Classe

5

Pedido

87818037

Registro

6540125

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

54

Atualização mais recente

21/09/2023

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5

Data de depósito

02/03/2018

Data de registro

26/10/2021

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

26/10/2021

Última transação

21/09/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use

Primeiro uso

01/08/2021

Primeiro uso no comércio

01/08/2021

Código do desenho

3

Tipo de titular

03

Localização do titular

New York City, NY

Examinador

MAYES, LAURIE

Unidade examinadora

L10

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The mark consists of the word "KNACK" in a stylized blue font in all uppercase letters, beneath which lies the word "PHARMACEUTICALS" in a second smaller stylized font in gray, to the left of which lies a stylized dark blue ribbon shape oriented horizontally with the legs of the ribbon extending outwards toward the right edge of the ribbon, with a light blue bar bisecting the top part of the ribbon, with the two stylized geometric shapes together comprising a stylized letter "K". Inside the "K" is a white diamond shape. Together the three literal elements form the combined phrase "K KNACK PHARMACEUTICALS".

Titulares e representantes

Titulares

KNACK PHARMACEUTICALS, INC.

Representantes

Tomas Maria Casalins Fox Horan & Camerini LLP

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseasesallergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the treatment and prevention of metabolicendocrine and kidney related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for treatment and prevention of viral and bacterial infections; Pharmaceutical preparationsinjectable contraceptives

Publicações

Histórico de despachos e eventos da marca no USPTO.

54 publicações encontradas

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

21/09/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

21/09/2023

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

21/09/2023

CCON

COUNTERCLAIM OPP. NO. 999999

11/07/2023

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

17/11/2021

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

17/11/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

17/11/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

17/11/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

26/10/2021

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

18/09/2021

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

17/09/2021

SUPC

STATEMENT OF USE PROCESSING COMPLETE

17/09/2021

IUAF

USE AMENDMENT FILED

10/09/2021

EISU

TEAS STATEMENT OF USE RECEIVED

10/09/2021

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

17/03/2021

EX5G

SOU EXTENSION 5 GRANTED

16/03/2021

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

16/03/2021

EXT5

SOU EXTENSION 5 FILED

02/03/2021

EEXT

SOU TEAS EXTENSION RECEIVED

02/03/2021

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

08/08/2020

EX4G

SOU EXTENSION 4 GRANTED

06/08/2020

EXT4

SOU EXTENSION 4 FILED

06/08/2020

EEXT

SOU TEAS EXTENSION RECEIVED

06/08/2020

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

07/03/2020

EX3G

SOU EXTENSION 3 GRANTED

05/03/2020

EXT3

SOU EXTENSION 3 FILED

05/03/2020

EEXT

SOU TEAS EXTENSION RECEIVED

05/03/2020

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

30/08/2019

EX2G

SOU EXTENSION 2 GRANTED

28/08/2019

EXT2

SOU EXTENSION 2 FILED

28/08/2019

EEXT

SOU TEAS EXTENSION RECEIVED

28/08/2019

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

06/03/2019

EX1G

SOU EXTENSION 1 GRANTED

04/03/2019

EXT1

SOU EXTENSION 1 FILED

04/03/2019

EEXT

SOU TEAS EXTENSION RECEIVED

04/03/2019

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

18/09/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

24/07/2018

PUBO

PUBLISHED FOR OPPOSITION

24/07/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/07/2018

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

19/06/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

18/06/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

18/06/2018

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

18/06/2018

GNEA

EXAMINERS AMENDMENT E-MAILED

18/06/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

18/06/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

15/06/2018

ALIE

ASSIGNED TO LIE

15/06/2018

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

14/06/2018

GNEA

EXAMINERS AMENDMENT E-MAILED

14/06/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

14/06/2018

DOCK

ASSIGNED TO EXAMINER

13/06/2018

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

10/03/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/03/2018

NWAP

NEW APPLICATION ENTERED

06/03/2018

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace K KNACK PHARMACEUTICALS ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.